Angiogenesis inhibitors in the treatment of prostate cancer

Author： Kluetz Paul G Figg William D Dahut William L

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.2, 2010-02, pp. : 233-247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Angiogenesis inhibitors in the treatment of cancer

By Rhee Jay Hoff Paulo M

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 10, 2005-08 ,pp. : 1701-1711

Informa Healthcare

Access to resources Recommend Favorite

Targeting angiogenesis for the treatment of prostate cancer

By Antonarakis Emmanuel S Carducci Michael A

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 4, 2012-04 ,pp. : 365-376

Informa Healthcare

Access to resources Recommend Favorite

CYP17 Inhibitors for Prostate Cancer Treatment - An Update

Current Medicinal Chemistry, Vol. 15, Iss. 9, 2008-04 ,pp. : 868-899

Bentham Science Publishers

Access to resources Recommend Favorite

Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer

By Edwards Joanne

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 5, 2010-05 ,pp. : 605-614

Informa Healthcare

Access to resources Recommend Favorite

VEGF Inhibitors and Prostate Cancer Therapy

Current Molecular Pharmacology, Vol. 2, Iss. 2, 2009-06 ,pp. : 161-168

Bentham Science Publishers

Access to resources Recommend Favorite